Results 41 to 50 of about 41,567 (239)

Cholinesterase Inhibitors: Structure of Eserine [PDF]

Nature, 1973
ESERINE (physostigmine) was first isolated from the Calabar bean in the latter half of the last century1, but it was not until much later that its activity on the heart was demonstrated to be due to inhibition of acetylcholinesterase2,3. It is one of the few compounds that are equally active as inhibitors of both true and pseudo-cholinesterase and has ...
T J, Petcher, P, Pauling
openaire   +2 more sources

Biological activities and chemical composition of methanolic extracts of selected Autochthonous microalgae strains from the Red Sea [PDF]

, 2015
Four lipid-rich microalgal species from the Red Sea belonging to three different genera (Nannochloris, Picochlorum and Desmochloris), previously isolated as novel biodiesel feedstocks, were bioprospected for high-value, bioactive molecules.
Carolina Bruno De Sousa, Florêncio Nogueira, Fouzi Mouffouk, Hugo Pereira, José Manuel, João Varela, Khalid M. Abu-salah, Luísa Barreira, Luísa Custódio, Maria João Rodrigues, Marta Oliveira, Nuno Da Rosa Neng, Radhouan Ben-hamadou, Salman A. Alrokayan, The Red Sea   +14 more
core   +4 more sources

In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor

Scientific Reports, 2023
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that is growing rapidly among the elderly population around the world.
Asma Gholami, Dariush Minai-Tehrani, Leif A. Eriksson   +2 more
doaj   +1 more source

Cholinesterase inhibitors from botanicals

Pharmacognosy Reviews, 2013
Alzheimer's disease (AD) is a progressive neurodegenerative disease, wherein a progressive loss of cholinergic synapses occurs in hippocampus and neocortex. Decreased concentration of the neurotransmitter, acetylcholine (ACh), appears to be critical element in the development of dementia, and the most appropriate therapeutic approach to treat AD and ...
Ahmed, Faiyaz, Ghalib, Raza Murad, Sasikala, P., Ahmed, K. K. Mueen   +3 more
openaire   +3 more sources

A NeuroD1 AAV‐Based Gene Therapy for Functional Brain Repair in Alzheimer's Disease‐Like Non‐Human Primate Model

Advanced Science, EarlyView.
This study tests NeuroD1 AAV‐based gene therapy in a non‐human primate Alzheimer's disease model. The therapy prevents neuronal damage, inhibits hippocampal atrophy, and reduces neuroinflammation. It also repairs vascular and blood‐brain barrier damage, restores cerebrospinal fluid biomarkers, enhances hippocampal glucose metabolism, and improves ...
Zhouquan Jiang, Yongpeng Qin, Bin Luo, Fan Bai, Jiangyue Liu, Long Ma, Shu He, Rongjie Chen, Yuchen Wang, Shanggong Liu, Ying Sun, Yi Chen, Shuo Zhang, Jiaqi Liang, Feng Liao, Huiyi Wei, Junjie Wei, Lu Wang, Hao Xu, Zheng Wu, Gong Chen, Wenliang Lei   +21 more
wiley   +1 more source

Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.

PLoS ONE, 2014
Patients with Alzheimer's disease after an initial response to cholinesterase inhibitors may complain a later lack of efficacy. This, in association with incident neuropsychiatric symptoms, may worsen patient quality of life.
Gianfranco Spalletta, Carlo Caltagirone, Alessandro Padovani, Sandro Sorbi, Mahmood Attar, Delia Colombo, Luca Cravello, E V O L U T I O N study Working Group   +7 more
doaj   +1 more source

The effects of novel 7-MEOTA-donepezil like hybrids and N-alkylated tacrine analogues in the treatment of quinuclidinyl benzilate-induced behavioural deficits in rats performing the multiple T-maze test

Biomedical Papers, 2015
Aims: The number of approved drugs for the clinical treatment of Alzheimer disease remains limited. For this reason, there is extensive search for novel therapies.
Jan Misik, Jan Korabecny, Eugenie Nepovimova, Pavla Cabelova, Jiri Kassa   +4 more
doaj   +1 more source

Brain and Liver Dual‐Targeting Oridonin Nanoparticles to Enhance Aβ Clearance for Alzheimer's Disease Therapy

Advanced Science, EarlyView.
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong, Wenting Hui, Sai Qiao, Qifeng Ji, Miao Liu, Bangle Zhang, Daozhou Liu, Yumei Wu, Siyuan Zhou   +8 more
wiley   +1 more source

Catecholamine-Based Treatment in AD Patients: Expectations and Delusions. [PDF]

, 2015
In Alzheimer disease, the gap between excellence of diagnostics and efficacy of therapy is wide. Despite sophisticated imaging and biochemical markers, the efficacy of available therapeutic options is limited.
Alessandro eStefani, Alessandro eStefani, Atticus H Hainsworth, Claudio eLiguori, Enrica eOlivola, Giacoma eAngileri, Mariangela ePierantozzi, Salvatore eGalati, Valentina eSaviozzi, Vincenza eD’Angelo   +9 more
core   +3 more sources

PharmVar GeneFocus: CYP1A2—Clinical Impact, Genetic Variation, and Updated Nomenclature

Clinical Pharmacology &Therapeutics, EarlyView.
The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human CYP1A2 gene. CYP1A2 plays a crucial role in the biotransformation of several commonly used drugs, including antipsychotics, antidepressants, anxiolytics, and methylxanthines.
Katalin Monostory, Gonzalo Villapalos Garcia, Dora Koller, Solomon Adams, Chad A. Bousman, Evangelia Eirini Tsermpini, Michelle Whirl‐Carrillo, Amy J. Turner, Volker M. Lauschke, Mohamed Nagy, Erin C. Boone, Teri E. Klein, Pablo Zubiaur, Andrea Gaedigk   +13 more
wiley   +1 more source